First Presentation of GLISSADE Results on the Glyder® Facet Restoration Device
MINNETONKA, Minn., Oct. 7, 2013 /PRNewswire/ -- Zyga Technology, Inc. today announced the first public presentation of early data from GLISSADE, a prospective, 40-patient trial that studied the GLYDER® Facet Restoration Device in the treatment of chronic facet joint pain. The presentation was made at the Annual Meeting of the German Society for Neurosurgery (DGNC), Spine Section, in Frankfurt, Germany. Preliminary data indicate a significant reduction in pain and improvement in function as measured by Visual Analogue Pain Scale (VAS) and Oswestry Disability Index (ODI).
"The Glyder data was received positively and with genuine interest by the Congress attendees," stated Konrad Seller, MD, who presented the data on September 27. "Facet restoration is an emerging area of study, since patients suffering from facetogenic low back pain do not have many long-term solutions when conservative treatments fail. The initial data demonstrated that a device-based approach provides pain reduction for periods up to 2 years. This has tremendous potential benefit for patients."
The Centers for Disease Control and Prevention lists low back pain (LBP) as the second most common cause of disability in US adults[i]. Ten percent of the U.S. population, over 31 million people, suffer from chronic low back pain[ii]. Approximately 31% of chronic low back pain is attributed to the facet joints[iii], small stabilizing joints located between and behind adjacent vertebrae.
"This is a significant milestone in the Glyder development process," said Jim Bullock, president and chief executive officer of Zyga. "We are encouraged by the strong surgeon interest and look forward to further demonstrating the clinical and economic value of the Glyder device through additional studies."
About Zyga Technology
Zyga Technology is dedicated to the research, development and commercialization of solutions that provide empirical clinical and economic value in the treatment of under-served conditions of the spine. The company is currently marketing the SImmetry® Sacroiliac Joint Fusion System, a minimally invasive procedure intended for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. Zyga Technology is headquartered in Minnetonka, Minn. For more information, visit www.zyga.com.
[i] Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults—United States, 1999. JAMA. 2001; 285(12):1571-1572.
[ii] Freuberger, JK et al. The Rising Prevalence of Low Back Pain. Arch Intern Med 2009; 169(3): 251 - 258.
[iii] DePalma M et al. What is the source of chronic low back pain and does age play a role? Pain Med 2011; 12:224 – 233.
Tel 612 698 9956
SOURCE Zyga Technology, Inc.